AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04141579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00457613
Drug: bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03070314
Drug: Echinaforce junior
RxNorm normalized name: Disprol Junior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea Purpurea Extract Pill, sweetened and with orange flavour
Trial: NCT02838225
Drug: Docetaxel, Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02838225
Drug: Docetaxel, Doxorubicin, Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03693599
Drug: Syntometrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 microgram of ergometrine diluted in 10 ml of Ringer's lactate solution and was administered intravenously over 2 minutes
Trial: NCT00730275
Drug: Comparator: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.
Trial: NCT03502031
Drug: Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maximal RAAS blockade alone or in combination with Spironolactone (25 mg) for 24 months.
Trial: NCT03093103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of a placebo once a day Follow-up of renal parameters including BOLD MRI
Trial: NCT02533700
Drug: CEOP/IVE/GDP chemotherapy regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5~IVE:~Ifosfamide 2000mg/m2,ivgtt D1-D3 Epirubucin 70mg/m2, ivgtt D1 Etoposide 100mg/m2, ivgtt D1-D3~GDP:~Gemcitabine 1g/m2,ivgtt D1,D8 Cis-platinum 25mg/m2, ivgtt D1-D3 Dexamethasone 40mg, ivgtt D1-D4
Trial: NCT02533700
Drug: CEOP chemotherapy regimen for 6 cycles
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
Trial: NCT05954052
Drug: Glutathione
RxNorm normalized name: Glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giving supplement orally
Trial: NCT02293941
Drug: JKB-122 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were randomized to receive JKB-122 5mg for 12 weeks
Trial: NCT00918749
Drug: 100 mg
RxNorm normalized name: urea 100 MG
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
Trial: NCT05110170
Drug: LY01005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.
Trial: NCT05110170
Drug: ZOLADEX® 3.6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.
Trial: NCT00830089
Drug: Levobupivicaine 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
Trial: NCT03130881
Drug: PLB1003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLB1003 is a capsule and is administered orally.
Trial: NCT01073787
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml/kg of normal saline will be administered over 30 minutes
Trial: NCT00712140
Drug: parenteral chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per the local institutional protocols either concurrently with or sequentially to trastuzumab
Trial: NCT00939822
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg Simvastatin/day
Trial: NCT00939822
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT00085787
Drug: ARRY-142886, MEK inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
Trial: NCT01903824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos formulated to match each active drug
Trial: NCT01978327
Drug: GSK2647544
FDA approved: no
EMA approved: no
PMDA approved: no
Description: repeat dose
Trial: NCT01145209
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01035645
Drug: GSK1070806
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drug, GSK1070806, is a humanised monoclonal antibody. Antibodies are proteins that are made by white blood cells during an immune reaction. They circulate in the blood and attach to foreign proteins called antigens in order to destroy or neutralise them.~Humanised monoclonal antibodies are a type of protein that is genetically engineered to resemble a human protein (humanised). GSK1070806 is designed to block a specific protein that exists in the body called Interleukin-18. Interleukin-18 works within the immune system, i.e. the body's defence system, which helps protect it from disease, bacteria and viruses. Interleukin-18 activates the immune system to fight infections and may also occasionally cause inflammation.
Trial: NCT00652327
Drug: Double Statin (simvastatin, atorvastatin, or pravastatin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 40 mg or atorvastatin 20 mg or pravastatin 40 mg once daily for 8 weeks
Trial: NCT04767243
Drug: open flap debridement and filled Bioactive glass (Perioglas®) and A-PRF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of perioglas with A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
Trial: NCT03943472
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300mg/m2/d
Trial: NCT03692429
Drug: CYAD-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
Trial: NCT03692429
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU, leucovorin and oxaliplatin
Trial: NCT03692429
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU, leucovorin and irinotecan
Trial: NCT03943472
Drug: Immune inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune inhibitors
Trial: NCT00004426
Drug: gonadotropin releasing hormone
RxNorm normalized name: Gonadotropin releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04155047
Drug: Placebo administered by Magnair
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Inhalation Solution
Trial: NCT01599494
Drug: MK-8962
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8962 is supplied in a ready-to-use prefilled syringe containing~100 microgram (μg) or 150 μg corifollitropin alfa per 0.5 mL. Participants are randomized to receive a single subcutaneous (SC) injection of MK-8962 in the abdominal wall on Cycle Day 2 or Cycle Day 3. Dose of administered MK-8962 is weight-based. Participants who weigh 60 kilograms (kg) or less will be given 100 μg MK-8962 and those who weigh more than 60 kg will be given 150 μg MK-8962.
Trial: NCT01599494
Drug: recFSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Follicle Stimulating Hormone (recFSH) will be supplied as a ready-to-use solution in a 600 IU cartridge for SC injection via the recFSH Pen. Starting on Day 2 or 3 of the menstrual cycle (Stimulation Day 1), recFSH will be administered daily, each morning, via injections in the abdominal wall. A starting dose of between 150 - 300 IU will be administered and is fixed for the first week of stimulation. After 6 days, and based on each participant's individual response, the Investigator may decide to reduce the fixed dose for the remainder of the study. The maximum duration of stimulation is 19 days; recFSH will not be administered on the Day of hCG Administration.
Trial: NCT04817332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT01635829
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=100, form=capsule, route=oral. Two capsules of phenytoin will be administered as per the dosing regimen in Part 2 of Panel 1.
Trial: NCT02293941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were randomized to receive comparable placebo for 12 weeks
Trial: NCT04514510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicified microcrystalline cellulose NF, Ascorbic acid, Nicotinic acid, Mg stearate, Silica and Colloidal Anhydrous Ph. Eur./Colloidal Silicon dioxide USP/NF.~Placebo give at 1000 mg, once daily by mouth for 28 days.
Trial: NCT03509922
Drug: Anplag Tab. 100mg bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sarpogrelate hydrochloride 100mg bid for 24 weeks
Trial: NCT01368263
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy
Trial: NCT03509922
Drug: Anplag Tab. 100mg tid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sarpogrelate hydrochloride 100mg tid for 24 weeks
Trial: NCT00507936
Drug: ABT-894
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-894 1 mg capsule BID throughout treatment period
Trial: NCT00507936
Drug: ABT-894
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-894 2 mg capsule BID throughout treatment period
Trial: NCT00507936
Drug: ABT-894
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-894 4 mg capsule BID throughout treatment period
Trial: NCT00507936
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule BID throughout the treatment period
Trial: NCT00972179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous or intravenous injection.
Trial: NCT01994720
Drug: Acetylsalicylic acid (ASA)
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA, 300 mg (three tablets of 100 mg) on Day 1, followed by 100 mg once daily.
Trial: NCT00110877
Drug: LPV/rtv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 400mg LPV tablet twice daily with 100mg RTV
Trial: NCT01152554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral, twice daily for 52 weeks
Trial: NCT00110877
Drug: TMC114/rtv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 300mg TMC114 tablets twice daily with 100mg RTV
Trial: NCT04078711
Drug: Qianyangyuyin 20g Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20g, Granule, bid, po, 6 months
Trial: NCT04078711
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar granule manufactured to mimic qianyangyuyin granule, 20g, Granule, bid, po, 6 months
Trial: NCT00190788
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02053493
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks 5 and 6: 120 mg Placebo~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo
Trial: NCT04086810
Drug: DCCR
RxNorm normalized name: Diazoxide Choline Controlled-Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral administration
Trial: NCT00847197
Drug: MK1903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
Trial: NCT02216383
Drug: Syntometrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntometrine, listed here, is one of the of the three study drugs.
Trial: NCT01534273
Drug: LY2886721
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT01534273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT01493245
Drug: JNS020QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During weeks 1-3, initial doses of 0.84 mg, 1.7 mg, 3.4 mg, or 5 mg can be increased until individual optimal dose (up to maximum 20.1 mg) is determined. The optimal dose will be administered during the maintenance period (1 week), followed by a long-term treatment (48 weeks) period, where the dose will be adjusted (escalated or reduced) in consideration of the efficacy of the study, and the condition of adverse events. The patches are applied on the skin and exchanged daily (every 24 hours) for consecutive 52 weeks.
Trial: NCT00847197
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
Trial: NCT00627055
Drug: LPV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/r dosing = 400mg/100mg orally q12h for 48 weeks
Trial: NCT00285025
Drug: SR57667B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03950843
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of CKD-825~* Dosage Form: capsule~* Dosage: NA~* Frequency: QD administration
Trial: NCT04563208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered on Days 1-5
Trial: NCT04563208
Drug: DuACT
RxNorm normalized name: Sus scrofa bile duct preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day1: RBV 600 mg BID and NTZ 500 mg BID Days 2-5: RBV 400 mg BID and NTZ 500 mg BID
Trial: NCT02854787
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A bolus of 0,2 mcg/kg
Trial: NCT01555476
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits
Trial: NCT01555476
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
Trial: NCT00627055
Drug: LPV/r + TDF/FTC or TDF/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF/FTC (Truvada) 1 pill orally q 24 hr or TDF 300mg orally q 24 hr/3TC 300mg orally q 24 hr (or 3TC 150mg orally q 12 hr) for 48 weeks
Trial: NCT02064348
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for s.c. injection or tablets for oral administration
Trial: NCT03949751
Drug: Acne Crème Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study specific intervention product is a combination of Benzoylperoxid and Miconazolnitrat (Widmer Acne Crème Plus, 47033 Swissmedic) to apply daily in the evening on the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae. The application should be done regularly for 7 days before shoulder surgery. The study specific intervention product is authorized by Swissmedic for use in the treatment of acne and is used standardly in clinical practice.
Trial: NCT03343327
Drug: Chronocort®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 20mg Chronocort® administered in one treatment period
Trial: NCT03343327
Drug: Cortef®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 20mg Cortef® administered in one treatment period
Trial: NCT02938741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-ATG 2.5MG/KG\*4days were not used in the conditioning
Trial: NCT00738894
Drug: Antiplatelet Medical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice of one of three regimen options specified in protocol
Trial: NCT03806101
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single 10 mg dose of rosuvastatin
Trial: NCT04064073
Drug: DWP16001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, once daily single dose
Trial: NCT00620165
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive identical placebo titrated up over 6 weeks to a maximum daily dose, and then continue twice daily for an additional 6 weeks.
Trial: NCT00633880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Trial: NCT02104297
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil infused during operation 0.2 mcg/kg/min
Trial: NCT02559895
Drug: ALD403
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02559895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02712905
Drug: INCB059872
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial cohort dose of INCB059872 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose(s) will be taken forward into expansion cohorts.~INCB059872 tablets to be administered by mouth.
Trial: NCT04870229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04751175
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01540864
Drug: HPP404
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily for 26 weeks
Trial: NCT01540864
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily for 26 weeks
Trial: NCT02217501
Drug: Acetylsalicylic acid (ASA)
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
Trial: NCT02111317
Drug: ASP015K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03504618
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of FOLFOXIRI regimen at first line with dosage:~Irinotecan: 165 mg / m2, intravenous infusion for 1 hour. Day 1, 15. Oxaliplatin: 85 mg / m2, intravenously for 2 hours Day 1, 15 Calcium folinate 200 mg / m2, intravenously for 2 hours Day 1, 15 5FU 3200 mg / m 2, intravenous infusion continuously for 48 hours Day 1, 2, 3, 15, 16, 17 Every 4 weeks. Each cycle has 2 infusion times, the first one is the first day, the second one is the 15th day
Trial: NCT01170325
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00768690
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.
Trial: NCT00768690
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.
Trial: NCT04675242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of NCX 4251 Ophthalmic Suspension dosed once daily
Trial: NCT00931632
Drug: Inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Nitric Oxide will be administered continuously starting at 20ppm into the inspiratory limb of the ventilator circuit in mechanically ventilated subject using an INOvent delivery system of by nasal cannula as needed for 24 days of therapy.
Trial: NCT00931632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrogen gas will be administered in the same manner as the experimental drug.
Trial: NCT00263198
Drug: PTK787/ZK222584
FDA approved: no
EMA approved: no
PMDA approved: no